Reference
Magliano CA, et al. Cost Effectiveness of Icatibant for Hereditary Angioedema in Brazil: Challenges in the Economic Evaluation of Orphan Drugs. 21st Annual International Meeting of the International Society for Pharmacoeconomics and Outcomes Research : (plus poster) abstr. PSY43, 21 May 2016. Available from: URL: http://www.ispor.org/research_study_digest/list.asp?qs=44905
Rights and permissions
About this article
Cite this article
Icatibant not cost effective for hereditary angioedema in Brazil. PharmacoEcon Outcomes News 755, 26 (2016). https://doi.org/10.1007/s40274-016-3133-y
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40274-016-3133-y